Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Another case of jaundice for RG-101.
Regulus Therapeutics
RGLS
RGLS
$1.16
$0.06
0.0%
BATS BZX Real Time Price as of June 21, 2019, 3:32 p.m.
View Interactive RGLS Charts
Regulus Therapeutics Inc.
News & Analysis: Regulus Therapeutics
Can These Upstarts Knock Gilead Sciences Off Its Perch?
Achlllion Pharmaceuticals and Regulus Therapeutics have set their sights on the highly lucrative hepatitis C market.
Why Regulus Therapeutics Inc. Fell 20.1% in April
Adverse events might sink the first candidate from an otherwise interesting platform.
Why Regulus Therapeutics Is Slumping 14% Today
Updated results for its clinical-stage hepatitis C drug failed to spark a rally.
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.
Why Shares of Regulus Therapeutics Skyrocketed Higher Today
The biopharma may have just hit pay dirt with its experimental hepatitis C treatment.
Why Regulus Therapeutics Inc. Shares Soared Higher Today
AstraZeneca Plc Inc is advancing Regulus Therapeutics' RG-125 into human trials.
2 Small Biotech Stocks Dreaming Big in Hepatitis C
Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.
Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?
AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.
How These 3 Stocks Doubled Investors' Money in Q4
Here's why Ovascience, Bluebird Bio, and Regulus investors saw their share prices surge last quarter.
